

6<sup>TH</sup> ESO-ESMO LATIN-AMERICAN **MASTERCLASS IN** CLINICAL ONCOLOGY

# 22-26 April 2020 Buenos Aires Argentina

**Chairs:** A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH

Scientific Co-ordinators: M. Aapro, CH - F. Cardoso, PT

Held in collaboration with



Under the auspices of



# LATIN-AMERICA PROGRAMME

#### FOREWORD

The Masterclass is the most structured ESO educational activity whose format has been established and presented in Europe for over a decade. The success of the teaching method has been confirmed by the events held also in other parts of the world as well as by the three editions held in Latin America. It is with pleasure and gratefulness for the consideration of the local community, that ESO announces the sixth edition to be held in the region in 2020.

The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based guidelines will be cited.

Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairs and the faculty.

As for all Masterclasses, the number of participants will be limited and admission will be by competitive application only.

Admitted participants will be granted free registration and half-board accommodation for the duration of the Masterclass.

#### **TEACHING FORMAT**

The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. The clinical sessions will be complemented by tumour board discussions supported by regional tutors.

Furthermore, participants will deliver case presentations within small groups and discuss these with the chairs and the faculty.

In preparation of the attendance, participants will be requested to follow four selected e-ESO sessions (www.e-eso.net).

All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.

#### LEARNING OBJECTIVES

- · Improve medical oncologists' skills
- Practising case discussions
- · Deep focus on breast, gastro-intestinal, genitourinary, gynaecological and lung cancers
- Compact update on further topics of interest

#### THE MASTERCLASS IS:

- A 5-day residential educational event
- Full immersion
- Clinically-oriented
- Multidisciplinary
- · Delivered by an international faculty of experts

#### IDEAL PROFILE OF THE MASTERCLASS CANDIDATE

- Age between 30 and 40 years
- At least 2-3 years' experience in medical oncology
- Involvement in scientific activities (desirable)
- At least an intermediate level of English language (simple scientific discussion in English)
- Practicing in Latin-America

#### LANGUAGE

The Masterclass will be held in English and translation will not be provided.

#### **INSURANCE**

The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants will be advised to take out their own personal and travel insurance coverage.

#### CME AND ESMO MORA ACCREDITATION AND CERTIFICATES

Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME). EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). Information on the status of the applications can be obtained from the organising secretariat. Participants will be entitled to receive a certificate of attendance at the close of the event by completing the on-line evaluation questionnaire.

Furthermore, application for the ESMO-MORA points is in process.

### **FACULTY** (as of December 2019)

- M.S. Aapro, Clinique de Genolier, Genolier, CH
- F. Cardoso, Champalimaud Cancer Center, Lisbon, PT
- F. Cavalli, Oncology Institute of Southern Switzerland, Bellinzona, CH
- A. Cervantes, University Clinical Hospital, Valencia, ES
- M. Chacon, Instituto Alexander Fleming, Buenos Aires, AR
- G. Curigliano, European Institute of Oncology, Milan, IT
- S.X. Franco, Clinical del Country, Bogota, CO
- G.H. Giornelli, Instituto Alexander Fleming, Buenos Aires, AR
- S. Iseas, Hospital Udaondo, Buenos Aires, AR
- D. Lorusso, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
- C. Martin, Instituto Alexander Fleming, Buenos Aires, AR
- N. Mottet, University Jean Monnet, Saint Etienne, FR
- J. Nadal, Instituto Alexander Fleming, Buenos Aires, AR
- N. Pavlidis, University Hospital, Ioannina, GR
- F.A. Peccatori, European School of Oncology and European Institute of Oncology, Milan, IT
- F. Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand, FR
- C. Rolfo, University of Maryland School of Medicine, Baltimore, US
- J.P. Sadé, Instituto Alexander Fleming, Buenos Aires, AR
- C. Sessa, Oncology Institute of Southern Switzerland, Bellinzona, CH
- R.A. Stahel, University Hospital, Zurich, CH
- E. Van Cutsem, University Hospital Gasthuisberg, Leuven, BE
- J.J. Zarbá, Hospital Zenon Santillan, San Miguel de Tucuman, AR

# PRELIMINARY PROGRAMME

### Wednesday, 22 April \_\_\_\_\_

12:15	Welcome and introduction	Chairs	
12:30	Clinical session <b>Gynaecological Cancers</b> <ul> <li>Pathologist's impact in gynaecological tumour</li> <li>Discussion</li> </ul>	<i>Chair:</i> C. Sessa, CH <i>Co-Chair:</i> TBC F. Penault-Llorca, FR	
	Ovarian Cancer: Surgical and systemic treatment     Discussion	D. Lorusso, IT	
	Endometrial Cancer: Local and systemic treatment     Discussion	C. Sessa, CH	
	<ul> <li>Cervical Cancer: Local and systemic treatment</li> <li>Discussion</li> </ul>	D. Lorusso, IT	
14:30	Coffee break		
14:50	Spotlight session <ul> <li>Primary and secondary prevention of cervical cancer</li> <li>Discussion</li> </ul>	J.J. Zarbá, AR	
15:20	Selected participants present their national situation • How is cancer treated in my country • Discussion		
15:40	<i>Tumour board</i> <b>Gynaecological Cancer</b> • Participants' case presentations	C. Sessa,CH - D. Lorusso, IT <i>Local tutor:</i> G. Giornelli, AR	
16:40	Group sessions • Clinical case presentations by participants Chairs 1: C. Sessa, CH - Co-chair: TBC Chair 2: D. Lorusso, IT - Co-chair: TBC		
17:40	The role of surgery in ovarian cancer - Video session • <i>Discussion</i>		
20:00	Welcome dinner		
Thursday, 23 April			
8:30	Clinical session <b>Breast cancer (I)</b> <ul> <li>What the clinician needs to know about breast pathology and sample quality</li> <li>Genomic tests in clinical practice</li> <li>Discussion</li> </ul>	Chair: F. Cardoso, PT - Co-Chair: TBC	
		F. Penault-Llorca, FR F. Cardoso, PT	
	<ul> <li>Discussion</li> <li>(Neo-) adjuvant chemotherapy and biological agents</li> <li>Discussion</li> </ul>	G. Curigliano, IT	
	<ul> <li>Neoadjuvant/adjuvant endocrine therapy</li> <li>Discussion</li> </ul>	F. Cardoso, PT	

10:50	Spotlight session <ul> <li>The reality of clinical trials in Latin America</li> <li>Discussion</li> </ul>	C. Rolfo, US
11:20	Clinical session Breast cancer (II)	Chair: C. Curigliano - Co-Chair: TBC
	Recommended management of HER-2+ advanced breast cancer	F. Cardoso, PT
	Discussion     Recommended management for triple-negative	
	advanced breast cancer • <i>Discussion</i>	G. Curigliano, IT
	<ul> <li>Recommended management for ER+ advanced breast cancer</li> <li><i>Discussion</i></li> </ul>	S.X. Franco. CO
13:05	Lunch	
14:00	<i>Tumour board</i> <b>Breast cancer</b> • Participant's case presentations	F. Cardoso, PT - G. Curigliano, IT S.X. Franco, CO <i>Local tutor:</i> J. Nadal, AR
16:00	Coffee break	
16:15	Group sessions • Clinical case presentations by participants Chair 1: F. Cardoso, PT - Co-Chair: J. Nadal, AR Chair 2 : G. Curigliano, IT - S.X. Franco, CO	
18:00	Spotlight session <ul> <li>Fertility preservation and pregnancy in cancer patients</li> <li>Discussion</li> </ul>	F. Peccatori, IT
Friday, a	24 April	
	Clinical session Lung cancer	<i>Chair:</i> R. Stahel, CH <i>Co-Chair:</i> C. Rolfo, US
	Advanced NSCLC with oncogenic driver mutation <i>Discussion</i>	C. Rolfo, US
•	Advanced NSCLC without oncogenic driver mutation <i>Discussion</i>	R. Stahel, CH
	Mutimodality treatment of stage III and oligometastatic NSCLC Discussion	C. Rolfo, US
•	Multimodality therapy of small cell lung cancer Discussion	R. Stahel, CH
10:30	Coffee break	
10:50	Selected participants present their national situation <ul> <li>How is cancer treated in my country</li> </ul>	
11:00	Discussion	
11:10	<i>Tumour board</i> <b>Lung cancer</b> • Participant's case presentations	R. Stahel, CH - C. Rolfo, US C. Martin, AR

13:00	Lunch	
14:00	Spotlight session  • Title to be confirmed	F. Cavalli, CH
14:35	• <i>Discussion</i> Group sessions <i>Chair 1: R. Stahel, CH - Co-Chair: C. Martin, AE</i> <i>Chair 2: C. Rolfo, US - TBC</i> Clinical case presentations by participants	
16:35	Coffee break	
16:55	Spotlight session • How to fight financial toxicity • Discussion	R. Stahel, CH
17:30	Spotlight session • Cancer of unknown primary • Discussion	N. Pavlidis, GR

Saturc	lay, 25	April
--------	---------	-------

Clinical session Gastro-intestinal tumours	<i>Chair:</i> E. Van Cutsem, BE <i>Co-chair:</i> A. Cervantes, ES
<ul> <li>What you have to obtain from the pathologists to make a good treatment decision</li> <li>Discussion</li> </ul>	F. Penault-Llorca, FR
Adjuvant and neo-adjuvant treatment of colorectal cancer     Discussion	E. Van Cutsem, BE
Systemic treatment in advanced CRC     Discussion	E. Van Cutsem, BE
<ul> <li>Management of early rectal Cancer</li> <li><i>Discussion</i></li> </ul>	A. Cervantes, ES
Coffee break	
Treatment of early esophageal and gastric cancer     Discussion	A. Cervantes, ES
<ul> <li>Systemic treatment of advanced gastric cancers</li> <li>Discussion</li> </ul>	E. Van Cutsem, BE
<ul> <li>Systemic treatment of pancreatic and biliary tract cancer</li> <li>Discussion</li> </ul>	E. Van Cutsem, BE
Selected participants present their national situation • How is cancer treated in my country • Discussion	
Tumour board Gastro-intestinal tumours	A. Cervantes, ES - E. Van Cutsem, BE <i>Tutor:</i> S. Iseas, AR
	<ul> <li>What you have to obtain from the pathologists to make a good treatment decision</li> <li><i>Discussion</i></li> <li>Adjuvant and neo-adjuvant treatment of colorectal cancer</li> <li><i>Discussion</i></li> <li>Systemic treatment in advanced CRC</li> <li><i>Discussion</i></li> <li>Management of early rectal Cancer</li> <li><i>Discussion</i></li> <li>Coffee break</li> <li>Treatment of early esophageal and gastric cancer</li> <li><i>Discussion</i></li> <li>Systemic treatment of advanced gastric cancers</li> <li><i>Discussion</i></li> <li>Systemic treatment of pancreatic and biliary tract cancer</li> <li><i>Discussion</i></li> <li>Selected participants present their national situation</li> <li>How is cancer treated in my country</li> <li>Discussion</li> </ul>

- **14:30** Spotlight session
  - Principles of geriatric oncology
  - Discussion
- **15:00** Group sessions *Chair 1: A. Cervantes, ES - Co-chair: S. Iseas, AR Chair 2: E. Van Cutsem, BE - Co-chair: TBC* • Clinical case presentations by participants
- **17:00** Coffee break
- **17:20** Spotlight session
  - How to operate colon cancer (video)
  - Discussion
- **20:15** Farewell dinner

### Sunday, 26 April \_\_\_\_\_

8:00	Clinical session Genito-urinary Cancers	<i>Chair:</i> N. Mottet, FR, BE - <i>Co-chair:</i> J.P. Sadé
	Management of localized prostate cancer     Discussion	N. Mottet, FR
	Treatment of metastatic castration sensitive prostate cancer     Discussion	J.P. Sadè, AR
	Castration-resistant prostate cancer     Discussion	N. Mottet, FR
	Treatment of bladder cancer     Discussion	J.P. Sadè, AR
	Metastatic renal cancer: Evidence-based treatment     Discussion	N. Mottet, FR
10:30	Coffee break	
10:50	<i>Tumour board</i> <b>Genito-urinary cancers</b> • Participant's case presentations	N. Mottet, FR - J.P. Sadè, AR – <i>Tutor:</i> M. Chacon, AR
11:50	Group sessions <i>Chair 1: N. Mottet, FR - Co-Chair:</i> M. Chacon, AR <i>Chair 2: J.P. Sadè, AR - Co-Chair: TBC</i> • Clinical case presentations by participants	
13:00	Learning assessment test	
14:00	Closing Remarks and Awards	
14:15	Lunch followed by departures	

M. Aapro, CH

## **GENERAL INFORMATION**

### **ORGANISING SECRETARIAT**

European School of Oncology Piazza Indipendeza 2 | 6500 Bellinzona | Switzerland Luis Carvalho Ph: +41 91 820 09 58 | E-mail: <u>lcarvalho@eso.net</u>

### ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY Successful applicants are granted free registration and accommodation APPLICATION DEADLINE: 12 JANUARY 2020

### Information and online application are available at www.eso.net

### **HOW TO APPLY**

Interested oncologists should apply online at www.eso.net providing the following documents:

- Letter describing motivation for attending;
- Support letter from head of department or mentor;
- CV with list of publications (if the list is not provided, it will be assumed that no papers have been published);
- Clinical case abstract (see below).

### Clinical case abstract

Applicants are requested to submit an abstract describing a clinical case related to one of the subjects of the Masterclass (breast, gastro-intestinal, genito-urinary, gynaecological and lung cancers).

It is suggested that, among the subjects of the Masterclass, the clinical case is on a tumour type that the applicant does not see frequently but that could add to the overall educational contents of the Masterclass. On the contrary, it is recommended that the case reflects the participant's daily practice, avoiding uncommon or extremely rare cases which may have a lower educational impact.

The clinical case abstract should include diagnostic considerations, treatment, results and follow-up, at least three questions proposed for discussion.

Admitted participants will have the opportunity to present the clinical case in the format of a clinical grand round discussion to the chairs, tutors, other faculty members and participants. The one-page abstract should be submitted on-line using the template available at www.eso.net, or by entering it in the application form.

The application outcome will be notified by e-mail by begin of February.